Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OTC coverage

This article was originally published in The Tan Sheet

Executive Summary

The Department of Defense will include OTCs found to be cost effective and therapeutically equivalent to Rx drugs in its formulary as part of a "demonstration project" under the John Warner National Defense Authorization Act For Fiscal Year 2007 (HR 5122), which was presented to the president for signing Oct. 5. DoD's Pharmacy & Therapeutics Committee will determine which OTCs qualify. The program will be implemented no later than May 1, 2007. DoD will evaluate the costs, benefits, clinical effectiveness and customer satisfaction of the program, and provide a report within two years of implementation to the Senate and House Committees on Armed Forces. The report will include proposed improvements and recommendations as to whether the department should have permanent authority to cover OTCs in its pharmacy benefits program...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS099832

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel